Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued on Friday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Trading Down 0.2 %

Shares of AEMD opened at $0.40 on Friday. The stock’s 50-day moving average price is $0.56 and its two-hundred day moving average price is $0.50. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $1.79. The company has a market capitalization of $5.80 million, a PE ratio of -0.25 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. Equities research analysts predict that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allegiance Financial Group Advisory Services LLC bought a new stake in Aethlon Medical in the fourth quarter worth approximately $26,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth approximately $81,000. Renaissance Technologies LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth approximately $25,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical in the 4th quarter valued at $31,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Aethlon Medical during the 4th quarter valued at $186,000. 1.99% of the stock is owned by institutional investors and hedge funds.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.